Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma

Rong, Zhuoxian; Li, Zhi; He, Junyang; Liu, Liyu; Ren, Xinxin; Gao, Jie; Mu, Yun; Guan, Yifu; Duan, Yumei; Zhang, Xiuping; Zhang, Dexiang; Li, Nan; Deng, Yuezhen; Sun, Lun‐Quan

doi:10.3389/fonc.2019.00369

Cited by 100 publications

(102 citation statements)

References 49 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…Second, an external validation is necessary to confirm the differential value of the nomogram. Finally, due to analysis based on clinicopathologic and serum data, specific markers such as PTTG and microRNA‐204, might further improve the accuracy of the nomogram …”

Section: Discussionmentioning

confidence: 99%

Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective To establish nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma (ICC) from hepatocellular carcinoma (HCC). Methods A cohort of 422 patients with HCC or ICC hospitalized at Xiangya Hospital between January 2014 and December 2018 was included in the study. Univariate and multivariate analysis was performed to identify the independent differential factors. Through combining these independent differential factors, a nomogram was established for differential diagnosis between ICC and HCC. The accuracy of nomogram was evaluated by using receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA). The results were validated using a prospective study on 98 consecutive patients operated on from January 2019 to November 2019 at the same institution. Results Sex (OR = 9.001, 95% CI: 3.268‐24.792, P < .001), hepatitis (OR = 0.323, 95% CI: 0.121‐0.860, P = .024), alpha‐fetoprotein (AFP) (OR = 0.997, 95% CI: 0.995‐1.000, P = .046), carbohydrate antigen 19‐9 (CA199) (OR = 1.016, 95% CI: 1.007‐1.025, P < .001), and aspartate transaminase‐to‐neutrophil ratio index (ANRI) (OR = 0.904, 95% CI: 0.843‐0.969, P = .004) were the independent differential factors for ICC. Nomogram was established with well‐fitted calibration curves through incorporating these 5 factors. Comparing model 1 including gender, hepatitis, AFP, and CA199 (C index = 0.903, 95% CI: 0.849‐0.957) and model 2 enrolling AFP and CA199 (C index = 0.850, 95% CI: 0.791‐0.908), the nomogram showed a better discrimination between ICC and HCC, with a C index of 0.920 (95% CI, 0.872‐0.968). The results were consistent in the validation cohort. DCA also confirmed the conclusion. Conclusion A nomogram was established for the differential diagnosis between ICC and HCC preoperatively, and better therapeutic choice would be made if it was applied in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Functionally, knockdown of FTO reduces the apoptosis of ICC cells and confers resistance to cisplatin treatment. In contrast, ectopic expression of FTO reduces ICC cell anchorageindependent growth and metastasis [77]. These conflicting functions of FTO in the two major types of primary liver cancer again raise the possibility of context-specific m6A landscapes and functions between HCC and ICC.…”

Section: The Implications Of M6a Modification In Liver Carcinogenesismentioning

confidence: 99%

The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis

2020

View full text Add to dashboard Cite

Liver cancer is a common cancer worldwide. Although the etiological factors of liver carcinogenesis are well defined, the underlying molecular mechanisms remain largely elusive. Epigenetic deregulations, such as aberrant DNA methylation and histone modifications, play a critical role in liver carcinogenesis. Analogous to DNA and core histone proteins, reversible chemical modifications on mRNA have recently been recognized as important regulatory mechanisms to control gene expression. N6-methyladenosine (m6A) is the most prevalent internal mRNA modification in mammalian cells. m6A modification is important for controlling many cellular and biological processes. Deregulation of m6A modification has been recently implicated in human carcinogenesis, including liver cancer. In this review, we summarize the recent findings on m6A regulation and its biological impacts in normal and cancer cells. We will focus on the deregulation of m6A modification and m6A regulators in liver diseases and liver cancers. We will highlight the clinical relevance of m6A deregulation in liver cancer. We will also discuss the potential of exploiting m6A modification for cancer diagnosis and therapeutics.

show abstract

“…N6-methyladenosine (m6A) modification is the most common modification in human mRNA [27], and it is considered as a new layer of epigenetic regulation on mRNA processing, translation [28] and stability [8,29]. Mounting evidence has proved that dysregulation of m6A modification is closely associated with various human physiological and pathological phenomena, including obesity, immuno-dysregulation, carcinogenesis [30,31] and so on [32,33]. As the development of the m6A-sequencing (m6A-seq) technology, it has been achieved to explore the roles of m6A mRNA modification in cancer biology [34,35].…”

Section: Discussionmentioning

confidence: 99%

Expression Status And Prognostic Value Of M6A-associated Genes in Gastric Cancer

Guan¹,

Liu²,

Li³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Purpose: Gastric cancer (GC) is a primary cause of cancer-associated mortality worldwide. N6-methyladenosine (m6A) is one of the most common RNA modifications that involves in the progression of numerous cancers. However, the expression status and function of m6A-related genes in gastric cancer is still not well understood. The current study is aimed to investigate the expression status and determinate prognostic value of m6A-related genes in gastric cancer. Methods: m6A-asssociated gene expression was evaluated via analyzing the expression data of GC patients from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database. The protein expression levels of m6A-associated molecules were further validated by immunohistochemical (IHC) staining data from GC tissue microarray (TMA) cohort and Human Protein Atlas (HPA) database. Kaplan-Meier analysis was performed to assess the prognostic value of m6A-associated genes in gastric cancer. Risk score model was established by lasso COX regression analysis and its prognostic predicted efficiency was assessed by the receiver-operator characteristic (ROC) curve. Cox regression analyses were used for exploring risk factors related to GC patient prognosis. Results: Most of m6A-related genes were upregulated at both mRNA and protein levels in gastric cancer tissues compared with that in normal gastric tissues. The expression levels of m6A-related genes were associated with clinicopathological features including race, age and TNM stage. High expression of WTAP and FTO predicted poor prognosis of GC patients. Survival analysis demonstrated that patients with high-risk scores had worse overall survival (OS) and ROC curves suggested the prediction performance for gastric patients. Moreover, Cox regression analyses indicated that m6A risk model score was a prognostic factor for OS and FTO upregulation might be a potential independent prognostic factor for recurrence-free survival (RFS) in gastric cancer patients. Conclusion: m6A-related genes were dysregulated in GC and were closely associated with prognosis of GC patients. FTO might serve as a novel prognostic biomarker for gastric cancer, while the m6A-related risk score might be informative for risk assessment and prognostic stratification.

show abstract

Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma

Cited by 100 publications

References 49 publications

Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis

Expression Status And Prognostic Value Of M6A-associated Genes in Gastric Cancer

Contact Info

Product

Resources

About